Immune characteristics of different immune phases in natural course of chronic HBV infection

Hepato-Gastroenterology

Volumn 60, Issue 124, 2013, Pages 789-795

  Ren, Yuan Yuan ^a   Liu, Yong Zhe ^a   Ding, Yu Ping ^a   Song, Ge ^a   Li, Shi Hong ^a   Wang, Gui Qiang ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Chronic; Hepatitis B virus; Immune tolerance; Infection

Indexed keywords

CD4 ANTIGEN; CD45RO ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 27; INTERLEUKIN 27 RECEPTOR; INTERLEUKIN 8; INTERLEUKIN RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNITY; IMMUNOFLUORESCENCE TEST; IMMUNOLOGICAL TOLERANCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION;

CASE-CONTROL STUDIES; CHEMOKINES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNE TOLERANCE; MALE; T-LYMPHOCYTE SUBSETS;

EID: 84879513793     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12907     Document Type: Article

References (30)

1. Ott JJ, Stevens GA, Groeger J, et al.: Global epidemiology of hepatitis B virus infection: new estimates of age-specific HB-sAg seroprevalence and endemicity. Vaccine 2012; 30:2212-2219.
2. Hui CK, Lau GKK: Current issues and future directions in treatment. Semin Liver Dis 2006; 26:192-197.
3. Liaw YF: Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29 Suppl 1:100-107.
4. Hui CK, Leung N, Yuen ST, et al.: Hong Kong Liver Fibrosis Study Group: Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007; 46(2):395-401. (Pubitemid 47344774)
5. Liaw YF, Chu CM: Hepatitis B virus infection. Lancet 2009; 373:582-592.
6. Ganem D, Prince AM: Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350:1118-1129. (Pubitemid 38298992)
7. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2001; 34:1225-1241. (Pubitemid 33096596)
8. The Guideline of Prevention and Treatment for Chronic Hepatitis B (2010 version). J Clini Hepatol 2011; 27(1)2000:324-329.
9. Lok ASF, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009; 50(3):661-662.
10. Bisceglie AM, Conjeevaram HS, Fried MW, et al.: Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:893-897.
11. Ishak KG, Baptista A, Bianchi L, et at.: Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
12. Keir ME, Butte MJ, Freeman GJ, Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704. (Pubitemid 351600389)
13. Day CL, Kaufmann DE, Kiepiela P. et al.: PD-1 expression on HIV-specific T cells is associated with T cell exhaustion and disease progression. Nature 2006; 443:350-354. (Pubitemid 44435155)
14. Boni C, Fisicaro P, Valdatta C, et al.: Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81:4215-4225. (Pubitemid 46586915)
15. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z: PD-1 upregulation- is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008; 45:963-970. (Pubitemid 350019503)
16. Iwai Y, Terawaki S, Ikegawa M, et al.: PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 2003; 198:39-50. (Pubitemid 36870184)
17. Karrar A, Broome U, Uzunel M, et al.: Human liver sinusoidal endothelial cells induce apoptosis in activated T cells: a role in tolerance induction. Gut 2007; 56:243-252.
18. Stoop JN, van der Molen RG, Baan CC, et al.: Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41:771-778. (Pubitemid 40462939)
19. Xu D, Fu J, Jin L, et al.: Circulating and liver resident CD4+CD25+regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177:739-747. (Pubitemid 43939189)
20. Sprengers D, Stoop JN, Binda RS, et al.: Induction of regulatory T-cells and interleukin-10-producing cells in nonresponders to pegylated interferon-alpha therapy for chronic hepatitis B. Antivir Ther 2007; 12:1087-1096. (Pubitemid 350114989)
21. Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL: Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 2007; 361:141-148. (Pubitemid 46551232)
22. Zhang JY, Song CH, Shi F, Zhang Z, Fu JL, Wang FS: Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. PLoS One 2010; 5(11):e13869.
23. Wojno ED, Hosken N, Stumhofer JS, et al.: A role for IL-27 in limiting T regulatory cell populations. J Immunol 2011; 187(1):266-273. Epub 2011; May 27.
24. Awasthi A, Carrier Y, Peron JP, et al.: A dominant function for interleukin 27 in generating interleukin 10-producing antiinflammatory T cells. Nat Immunol 2007; 8:1380-1389. (Pubitemid 350131175)
25. Fitzgerald DC, Zhang GX, El-Behi M, et al.: Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007; 8:1372-1379. (Pubitemid 350131174)
26. Stumhofer JS, Silver JS, Laurence A, et al.: Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007; 8:1363-1371. (Pubitemid 350131173)
27. Murugaiyan G, Mittal A, Lopez-Diego R, Maier LM, Anderson DE, Weiner HL: IL-27 is a key regulator of IL-10 and IL-17 production by human CD41T cells. J Immunol 2009; 183:2435-2443.
28. Zhu C, Zhang R, Liu L, et al.: Hepatitis B virus enhances interleukin-27 expression both in vivo and in vitro. Clin Immunol 2009; 131(1):92-97. Epub 2008 Dec 9.
29. Oh JW, Schwiebert LM, Benveniste EN: Cytokine regulation of CC and CXC chemokine expression by human astrocytes. J Neurovirol 1999; 5(1):82-94. (Pubitemid 29051882)
30. Farber JM: Mig and IP-10: CXC chemokines thattarget lymphocytes. J Leukoc Biol 1997; 61:246-257.